| 2026-08-31 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-25 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-10 | Press release | Press release · Aug 2026 |
| 2026-08-10 | Press release | Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio |
| 2026-08-10 | 8-K | Form 8-K, Item 7.01 |
| 2026-08-10 | 8-K | Form 8-K, Item 1.01 |
| Transcript | Q2 FY26 earnings call transcript |
| 2026-08-03 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-03 | Press release | Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results |
| 2026-08-03 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-03 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-24 | 8-K | Form 8-K, Item 5.07 |
| 2026-07-20 | Press release | Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 |
| 2026-07-20 | Press release | Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 |
| 2026-06-17 | Press release | Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies |
| 2026-06-17 | Press release | Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies |
| 2026-06-16 | Press release | Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia |
| 2026-06-16 | Press release | Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia |
| 2026-06-12 | Press release | Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer |
| 2026-06-12 | Press release | Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer |
| 2026-06-08 | Proxy | Definitive proxy statement |
| 2026-06-04 | Press release | Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia |
| 2026-06-04 | Press release | Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia |
| 2026-05-29 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-27 | Press release | Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA |
| 2026-05-27 | Press release | Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA |
| 2026-05-12 | Press release | Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-05-12 | Press release | Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-05-05 | Deck | 2026 First Quarter Financial Results |
| 2026-05-05 | Press release | Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results |
| 2026-05-05 | Press release | Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-01 | Deck | Corporate Overview May 2026 |
| 2026-04-27 | Press release | Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA |
| 2026-04-27 | Press release | Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA |
| 2026-04-24 | 10-K | Annual report on Form 10-K/A, FY25 |
| 2026-04-21 | Press release | Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 |
| 2026-04-21 | Press release | Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin) |
| 2026-04-21 | Press release | Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 |